



TFOS meeting - Cernobbio, Italy

15 minute talks, 10 minute discussion

Impact of glaucoma medications on the ocular surface* and how ocular surface disease can influence glaucoma treatment

Moderators

- · Christophe Baudouin (Quinze-Vingts National Eye Hospital & Vision Institute, Paris, France)
- · Miriam Kolko (Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen; Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark)
- · David A Sullivan (TFOS, and recently Schepens Eye Research Institute & Harvard Medical School, Boston, MA)
- * The term "ocular surface" encompasses the surface (cornea & conjunctiva), tear film, and adnexa (lacrimal and meibomian glands).

Opening remarks

8:00 Amy Gallant Sullivan (Executive Director, Tear Film & Ocular Surface Society, Boston, MA, USA)

Introduction

8:05 TFOS: Global mission - David A Sullivan

Epidemiology, pathophysiology and treatment of glaucoma

8:20 Epidemiology and pathophysiology of glaucoma -Miriam Kolko

8:45 Therapeutic approaches for glaucoma treatment: Generics versus brand-named drugs -Verena Prokosch-Willing (University of Cologne, Cologne, Germany)











Impact of topical glaucoma medications on the ocular surface and adnexa 9:10 Prevalence of, and risk factors for, ocular surface disease in glaucoma patients -Elisabeth Messmer (Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany) 9:35 Adverse effects of active ingredients in glaucoma medications on the ocular surface and adnexa - Fredrik Fineide and Tor Paaske Utheim (Department of Ophthalmology, Oslo University Hospital, Oslo, Norway) 10:00 Adverse effects of active ingredients in glaucoma medications on the nasolacrimal duct and periorbital area -Rachna Murthy (Face Restoration, London, UK) 10:20 Coffee/tea break

10:40 Adverse effects of BAK preservatives in glaucoma medications - Françoise Brignole-Baudouin (Institut de la Vision, Sorbonne Université, Paris, France) 11:05 Adverse effects of non-BAK preservatives in glaucoma medications - Anton Hommer (Department of Ophthalmology, HERA Hospital, Vienna, Austria) 11:30 Adverse effects of antimetabolite treatments following glaucoma filtration surgery - Gus Gazzard (Moorfields Eye Hospital, London, UK) 11:55 Treatment outcomes: Tolerability, compliance and quality of life - Andrew J Tatham (Princess Alexandra Eye Pavilion and Department of





Impact of pre-existing ocular surface disease on glaucoma treatment - both surgical and medical

1:50 Management of ocular surface disease in glaucoma patients - Christophe Baudouin (Quinze-Vingts National Eye Hospital & Vision Institute, Paris, France)

2:15 Management of glaucoma in ocular surface disease patients -Barbara Cvenkel (Ljubljana University Medical Centre, Ljubljana, Slovenia)

Therapeutic challenges

2:40 Bottleneck in bottle design -Sofie Beier (School of Design, The Royal Danish Academy of Fine Arts, Copenhagen, Denmark) 3:05 How could we improve glaucoma treatment care - the way to the heart of the politician -Marijke Vittrup (President, Fight for Sight, Copenhagen, Capital Region, Denmark)

3:30 Point of view of glaucoma treatment from a patient with ocular surface disease - Erik Jespersen (Denmark) 3:55 Coffee/tea

Future research recommendations

4:15 Anne Hedengran Nagstrup (Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen; Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark)

4:20 Fredrik Fineide (Department of Ophthalmology, Oslo University Hospital, Oslo, Norway) 4:25 Francesco Oddone (Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy)

Conclusions


4:30 Francesco Oddone

Closing remarks

4:40 Miriam Kolko











REGISTRATION

Registration Fee: Euro 60,00 VAT Included

Meeting, Lunch and 2 Coffee Breaks included

For registration: http://reg.jaka.it/index.php

The deadline for online registration is October 10, 2022



